This is a demo store. No orders will be fulfilled.

Novartis patent anti-PMEL17 (anti-PMEL) - Primary antibody, specific to PMEL

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Cynomolgus monkey,Human,Mouse,Rat
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
In stock
Item Number
Ab209871
Grouped product items
SKU Size
Availability
Price Qty
Ab209871-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$109.90
Ab209871-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$509.90
Ab209871-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,399.90
Ab209871-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,299.90

Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Novartis patent anti-PMEL17 (anti-PMEL) - Primary antibody, specific to PMEL
Synonyms 95 kDa melanocyte specific secreted glycoprotein antibody | 95 kDa melanocyte-specific secreted glycoprotein antibody | D12S53E antibody | gp100 antibody | M-beta antibody | ME20 antibody | ME20 M/ME20 S antibody | ME20-M antibody | ME20-S antibody | ME20
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Biochemical and Physiological Mechanisms Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distin
Host species Human
Specificity PMEL
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Product Description

Novartis patent anti-PMEL17 (anti-PMEL) is a monoclonal antibody targeting human PMEL protein. It is used as a target for antibody drug conjugate (ADC) therapy in melanoma.

Product Properties

Light Chain Type lambdaC2
SDS-PAGE 145.38 kDa
Purification Method Protein A purified
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Associated Targets(Human)

PMEL Tclin Melanocyte protein PMEL (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Novartis patent anti-PMEL17 (anti-PMEL) (Ab209871) - Flow Cytometry
Flow Cytometry analysis of pLVX-puro-CRS-hu-PMEL-FL cells labelling PMEL at 1×105 cell/well can bind Novartis patent anti-PMEL17 (anti-PMEL) (Ab209871), with the EC50 is 0.16 nM.

Novartis patent anti-PMEL17 (anti-PMEL) (Ab209871) - SEC
The purity of Novartis patent anti-PMEL17 (anti-PMEL) (Ab209871) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.